Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jirarat Poohadsuan"'
Autor:
Sudjit Luanpitpong, Montira Janan, Juthamas Yosudjai, Jirarat Poohadsuan, Pithi Chanvorachote, Surapol Issaragrisil
Publikováno v:
International Journal of Molecular Sciences; Volume 23; Issue 22; Pages: 14474
Mantle cell lymphoma (MCL) is an aggressive non-Hodgkin lymphoma with poor prognosis, due to the inevitable development of drug resistance. Despite being the first-in-class proteasome inhibitor for relapsed/refractory MCL, resistance to bortezomib (B
Autor:
Chayanin Kiratipaiboon, Yon Rojanasakul, Surapol Issaragrisil, Jirarat Poohadsuan, Sudjit Luanpitpong, Parinya Samart
Publikováno v:
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1864:3739-3753
Mantle cell lymphoma (MCL) is an aggressive, incurable non-Hodgkin B-cell lymphoma with good initial response to therapy then subsequently relapse. Cancer stem cells (CSCs) are considered to be an underlying cause of these inevitable drug resistance
Autor:
Surapol Issaragrisil, Yaowalak U-Pratya, Parinya Samart, Montira Janan, Jirarat Poohadsuan, Yon Rojanasakul, Nawin Chanthra, Sudjit Luanpitpong
Publikováno v:
Molecular Cancer Therapeutics. 17:484-496
Aberrant energy metabolism represents a hallmark of cancer and contributes to numerous aggressive behaviors of cancer cells, including cell death and survival. Despite the poor prognosis of mantle cell lymphoma (MCL), due to the inevitable developmen
Autor:
Jirarat Poohadsuan, Napachai Rodboon, Surapol Issaragrisil, Kanjana Thumanu, Sudjit Luanpitpong, Phatchanat Klaihmon, Montira Janan
Publikováno v:
Cancers, Vol 11, Iss 4, p 576 (2019)
Cancers
Volume 11
Issue 4
Cancers
Volume 11
Issue 4
Despite overall progress in improving cancer treatments, the complete response of mantle cell lymphoma (MCL) is still limited due to the inevitable development of drug resistance. More than half of patients did not attain response to bortezomib (BTZ)